Human Nectin-2 / CD112 Protein, Fc Tag, 100µg

Background
Poliovirus receptor-related 2 (PVRL2) is also known as nectin-2 and CD112 (formerly herpesvirus entry mediator B, HVEB), which is a human plasma membrane glycoprotein. PVRL2 is one of the plasma membrane components of adherens junctions. PVRL2 also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and it is involved in cell to cell spreading of these viruses. Variations in PVRL2 gene have been associated with differences in the severity of multiple sclerosis. Also, PVRL2 binds with low affinity to TIGIT. Furthermore, PVRL2 acts as a receptor for herpes simplex virus 1 (HHV-1) mutant Rid1, herpes simplex virus 1 (HHV-2) and pseudorabies virus (PRV).

Source
Recombinant Human Nectin-2, Fc Tag (PV2-H5253) is expressed from human 293 cells (HEK293). It contains AA Gln 32 - Leu 360 (Accession # Q92692-2).
Predicted N-terminus: Gln 32

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 62.2 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Anti-tumor activity of a recombinant measles virus against canine lung cancer cells"
Tamura, Fujiyuki, Moritoh et al
Sci Rep (2023) 13 (1), 18168
(2) "Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for NK-cell therapy in acute myeloid leukemia"
Kaito, Sugimoto, Nakamura et al
Haematologica (2023)
(3) "[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma]"
Klümper, Eckstein, Kunath et al
Urologie (2023)
Showing 1-3 of 816 papers.